Antiviral drug remdesivir has “little or no effect” on a hospitalised Covid-19 patients’ chances of survival, a World Health Organisation (WHO) clinical trial has suggested.

The European Commission says it has sealed a deal with pharmaceutical company Gilead to buy 500,000 treatment courses of remdesivir.